Skip to main content

dapoxetine

 

Following non-submission

AWMSG advice
Status: Not endorsed (Statement of Advice)

In the absence of a submission from the holder of the marketing authorisation, dapoxetine (Priligy®) cannot be endorsed for use within NHS Wales for the treatment of premature ejaculation in men aged 18 to 64 years old.

Dapoxetine is being considered for suitability for AWMSG assessment by the AWMSG Scrutiny Panel at their meeting on 09/07/2026.
 Statement of Advice (SOA): dapoxetine (Priligy) 1671 (PDF, 38Kb)

Medicine details
Medicine name dapoxetine
Formulation 30 mg and 60 mg film-coated tablet
Reference number 1671
Indication

Treatment of premature ejaculation (PE) in adult men aged 18 to 64 years. Dapoxetine should only be prescribed to patients who meet all the following criteria:

  • An intravaginal ejaculatory latency time (IELT) of less than two minutes; and
  • Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and
  • Marked personal distress or interpersonal difficulty as a consequence of PE; and
  • Poor control over ejaculation; and
  • A history of premature ejaculation in the majority of intercourse attempts over the prior 6 months.

Dapoxetine should be administered only as on-demand treatment before anticipated sexual activity. Dapoxetine should not be prescribed to delay ejaculation in men who have not been diagnosed with PE.
Company various
BNF chapter Obstetrics, gynaecology & urinary tract disorders
Assessment type Non-submission
Status Not endorsed (Statement of Advice)
Scrutiny Panel meeting date 09/07/2026
Date of issue 07/08/2012
Further information

Dapoxetine is being considered for suitability for AWMSG assessment by the AWMSG Scrutiny Panel at their meeting on 09/07/2026.
Follow AWTTC: